Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States

IF 7.2 2区医学 Q1 IMMUNOLOGY

Emerging Infectious Diseases Pub Date : 2025-05-14 DOI:10.3201/eid3106.241519

Anatevka S. Ribeiro, Andrew B. Wolf, Ellen W. Leschek, Lawrence B. Schonberger, Joseph Y. Abrams, Ryan A. Maddox, Brian S. Appleby, Katie Glisic, Aaron Carlson, Elizabeth Matthews

引用次数: 0

Abstract

We report a case of iatrogenic Creutzfeldt-Jakob disease (iCJD) after a 48.3-year incubation period in a patient treated with cadaveric human growth hormone. iCJD was pathologically confirmed; genetic analysis was negative for pathogenic mutations. Clinicians should consider iCJD in patients with progressive neurologic signs who had received cadaveric human growth hormone treatment.

查看原文本刊更多论文

长潜伏期的尸体人类生长激素相关克雅氏病，美国

我们报告一例医源性克雅氏病（iCJD）经过48.3年的潜伏期治疗的病人尸体人生长激素。病理证实为iCJD；遗传分析未发现致病性突变。临床医生应考虑接受尸体人类生长激素治疗的进行性神经症状患者的iCJD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging Infectious Diseases 医学-传染病学

CiteScore

17.30

自引率

1.70%

发文量

505

审稿时长

1 months

期刊介绍： Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination. Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.